EGFR and acute myeloid leukemia: Although the pharmacological inhibition of EGFR plays no role in the treatment of AML, chronic exposure to oxidative stress drives resistance to EGFR-targeted therapies such as afatinib [100], providing a mechanism by which ROS promote resistance to targeted therapies.